SWA
JAZZ icon

Stratos Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stratos Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,428
Closed -$236K – 486
2020
Q4 		$236K Buy
+1,428
New +$213K 0.03% 356

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Stratos Wealth Advisors's JAZZ Position: Q1 2021 in Review

Stratos Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 1,428 shares — an estimated $236K sold.

Stratos Wealth Advisors first reported a position in JAZZ in Q4 2020 and held it in 1 quarter. The position peaked at $236K in Q4 2020. 442 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Stratos Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Stratos Wealth Advisors sold 1,428 Jazz Pharmaceuticals shares in Q1 2021, an estimated $236K.
  • Stratos Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Stratos Wealth Advisors's Jazz Pharmaceuticals position peaked at $236K in Q4 2020.
  • 442 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Stratos Wealth Advisors's 13F filing for Q1 2021, filed 27 Apr 2021.